Safety and tolerability of the combination of simvastatin plus rifaximin in patients with decompensated cirrhosis: a multicenter, double-blind, placebo controlled randomized clinical trial.

Trial Profile

Safety and tolerability of the combination of simvastatin plus rifaximin in patients with decompensated cirrhosis: a multicenter, double-blind, placebo controlled randomized clinical trial.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2018

At a glance

  • Drugs Rifaximin (Primary) ; Simvastatin (Primary)
  • Indications Liver cirrhosis
  • Focus Adverse reactions
  • Acronyms LIVERHOPE
  • Most Recent Events

    • 13 Apr 2018 This trial has been completed in Netherlands, according to European Clinical Trials Database.
    • 19 Mar 2018 This trial has been completed in Spain, according to European Clinical Trials Database.
    • 06 Mar 2018 Planned End Date changed from 10 Dec 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top